Targeted
protein
degradation
beyond
conventional
limits.
We develop smaller protein degrader therapeutics to reach new biological targets and bigger populations. First stop: neurodegenerative disease.
First-generation protein degraders are limited
Targeted protein degraders use the cell’s natural protein-clearance machinery to remove disease-driving proteins rather than simply inhibiting them. This ability to eliminate, rather than block, opens up a new frontier in drug discovery. But emerging degrader types each bring their own opportunities and challenges.
Bifunctional degraders
modular
BULKY
Bifunctional degraders have modular components, but their large size limits oral bioavailability and penetration into tissues like the brain.
Molecular glues
drug-like
serendipitous
Molecular glues are smaller and have more favourable drug-like characteristics, but do not offer the same rational, modular design approach.
What
if
you
could
com
bine
the
advantages
of
both?
Introducing Our SELFTAC Platform
Bifunctional degraders are powerful but often too large to efficiently cross biological barriers.
Our proprietary platform allows degraders to travel as smaller components before self-assembling into their active form.
.png)
Separate
SELFTACs exist as two small molecules designed to cross biological membranes like the gut wall, cell membranes and the blood-brain-barrier
.png)
Assemble
Once across the blood-brain barrier, the components reversibly self assemble into an active bifunctional degrader with rational drug design
Degrade
Once assembled, the SELFTAC behaves like a standard PROTAC, summoning the cell’s natural protein-clearance machinery to remove the target protein.
The
function
of
a
full
degrader
.png)
The
distribution
of
a
small
molecule.
Protein
degradation
unlocked
SELFTAC® enables a faster, more modular approach to developing oral and CNS-penetrant degraders, transforming how they are discovered and developed.
Key Features:
High Oral Bioavailability
Make oral degraders the expectation, not the exception.
Routine CNS penetration
Open the brain to protein degrader therapeutics
Faster, more efficient discovery
Turn iterative chemistry into modular design with reusable components
Integrate new technology
Integrate emerging E3 ligases to expand target applications.
Protein
degradation
unlocked
SELFTAC® enable a faster, more modular approach to developing oral and CNS-penetrant degraders, transforming how they are discovered and developed.
Key Features:
High Oral Bioavailability
Make oral degraders the expectation, not the exception.
Routine CNS penetration
Open the brain to protein degrader therapeutics
Faster, more efficient discovery
Turn iterative chemistry into modular design with reusable components
Integrate new technology
Integrate emerging E3 ligases to expand target applications.
First,
we’re
taking
on
Tau
Our first focus is developing an oral degrader designed to selectively remove pathological forms of tau while preserving healthy tau in Alzheimer’s disease.
Key Features:
Remove pathological tau
Target the forms of tau associated with disease.
Preserve healthy tau
Build selectivity into the therapeutic approach.
Reach the brain
Achieve broad distribution and deep penetration of the brain.
Enable oral administration
A medicine that can be accessed by a broad global patient population.
First,
we’re
taking
on
Tau
Our first focus is developing an oral degrader designed to selectively remove pathological forms of tau while preserving healthy tau in Alzheimer’s disease.
Key Features:
Remove pathological tau
Target the forms of tau associated with disease.
Preserve healthy tau
Build selectivity into the therapeutic approach.
Reach the brain
Achieve broad distribution and deep penetration of the brain.
Enable oral administration
A medicine that can be accessed by a broad global patient population.
Leadership Team
Investors
.png)
Board of Directors
Clive Dix Chairman
Tim Clackson Non-Exec Director
Owen Smith Non-Exec Director
Chaya Patel Non-Exec Director
Craig Fox Non-Exec Director
Raghd Rostrom Non-Exec Director
Rob Johnson Chief Executive Officer
Founders
Harry Finch
Harry founded the company in 2020, bringing decades of pharmaceutical experience in medicinal chemistry, drug discovery and development. He is co-inventor of GSK’s successful asthma drug salmeterol (Serevent), developed during a career spanning Ciba-Geigy (now Novartis), Roche and Glaxo, where he became Director of Chemistry at GlaxoWellcome. He later worked at biotechs including Vernalis and Argenta Discovery, advised small biotechs and investors as an independent consultant, and served as a non-executive director of C4X Discovery, Pulmocide Therapeutics and Artios Pharma. Harry holds a PhD in Organic Chemistry.
LinkedInStephen Haggarty
Stephen is Professor of Neurology at Massachusetts General Hospital and Harvard Medical School, where he directs the Chemical Neurobiology Laboratory in the Center for Genomic Medicine. His research combines chemical biology with patient-derived stem cell models to understand and target the mechanisms behind neuropsychiatric and neurodegenerative disorders, including Alzheimer’s disease and frontotemporal dementia. In collaboration with Eric Fischer, his lab showed that targeted degraders can clear aberrant tau in neurons derived from patients with frontotemporal dementia. Together they founded Proximity Therapeutics to progress this research.
LinkedinEric Fischer
Eric is Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and directs the Chemical Biology Program and the Center for Protein Degradation at Dana-Farber Cancer Institute. A structural and chemical biologist, he is recognised as one of the leading experts in targeted protein degradation. During his doctoral studies at the Friedrich Miescher Institute in Basel, his work helped reveal how thalidomide works, laying foundations for the molecular glue field. He has co-founded several degrader companies, including Civetta Therapeutics, Neomorph and Proximity Therapeutics.
Linkedin
Join the team
Join a team driven by scientific conviction, intellectual honesty and the ambition to build better medicines for patients.
News & PR
Designed for better medicines
News
Link to press releases just the new one to go out shortly
Sample Name Health World Model: A Living Understand.....
How our Health World Model connects a patient’s history to today’s care and builds toward predicting what comes next.
Concurrence Health World Model: A Living Understand.....
How our Health World Model connects a patient’s history to today’s care and builds toward predicting what comes next.
Concurrence Health World Model: A Living Understand.....
How our Health World Model connects a patient’s history to today’s care and builds toward predicting what comes next.